Form 4: Pfizer CFO David Denton Acquires Stock Appreciation Rights

Pfizer's Chief Financial Officer, David M. Denton, acquired stock appreciation rights (SARs) that will be settled in shares of Pfizer common stock, according to a recent SEC filing.

Summary

• David M. Denton, the Chief Financial Officer & EVP of Pfizer Inc., reported changes in beneficial ownership to the SEC.
• On February 27, 2024, Denton acquired 161,160 stock appreciation rights (SARs) with an exercise price of $26.89, which will be settled in Pfizer common stock on February 27, 2029, subject to vesting requirements.
• Denton also acquired 142,400 stock appreciation rights (SARs) with an exercise price of $26.89, which will be settled in Pfizer common stock on February 27, 2031, subject to vesting requirements.
• Following these transactions, Denton directly owns 161,160 and 142,400 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock appreciation rights by the CFO suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock appreciation rights by a key executive like the CFO can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth and seventh anniversary of the grant date.

Industry Context

Executive compensation often includes stock-based awards like SARs to align management's interests with those of shareholders, incentivizing long-term value creation. This is a common practice in the pharmaceutical industry.

Comparison to Industry Standards

• Companies like Johnson & Johnson (JNJ) and Merck & Co. (MRK) also utilize stock appreciation rights as part of their executive compensation packages.
• The vesting schedules and settlement terms are generally in line with industry practices, typically ranging from three to seven years.

Stakeholder Impact

• The acquisition of stock appreciation rights aligns the CFO's interests with those of shareholders, potentially incentivizing decisions that increase shareholder value.

Key Dates